Scarica l'app Stockscreener
24.89
2.77%
0.67
Dopo l'orario di chiusura:
24.89
Arrivent Biopharma Inc Borsa (AVBP) Ultime notizie
Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline Interest - Yahoo Finance
AVBP Technical Analysis & Stock Price Forecast - Intellectia AI
Avoiding Lag: Real-Time Signals in (AVBP) Movement - Stock Traders Daily
Clear Street Initiates Coverage of ArriVent BioPharma (AVBP) with Buy Recommendation - MSN
ArriVent to present preclinical cancer drug data at AACR 2026 - MSN
Gains Report: Whats next for ArriVent BioPharma Inc stock2026 Technicals & Weekly Breakout Stock Alerts - baoquankhu1.vn
Aug Highlights: How do insiders feel about ArriVent BioPharma IncAnalyst Upgrade & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
ArriVent BioPharma (NASDAQ:AVBP) Trading Up 8.4%Here's Why - MarketBeat
Aug Mood: Can ArriVent BioPharma Inc maintain sales growth2026 Investor Takeaways & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum Shift - Sahm
RONB Should I Buy - intellectia.ai
BCSM Should I Buy - intellectia.ai
GLND Should I Buy - Intellectia AI
DNMXU Should I Buy - Intellectia AI
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year? - Yahoo Finance
ArriVent BioPharma (NASDAQ:AVBP) Upgraded to Strong-Buy at Truist Financial - MarketBeat
MQY Should I Buy - Intellectia AI
VCX Should I Buy - Intellectia AI
Burkina Faso Integrates National Languages into AI Development Strategy - techafricanews.com
Weekly Investment Analysts’ Ratings Changes for ArriVent BioPharma (AVBP) - defenseworld.net
ArriVent to Present Preclinical Cancer Drug Data at AACR 2026 - mychesco.com
ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib (NASDAQ:AVBP) - Seeking Alpha
Discipline and Rules-Based Execution in AVBP Response - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $45.00 at B. Riley Financial - MarketBeat
B. Riley Securities Maintains Buy on ArriVent... - Benzinga
Arrivent Biopharma, Aveanna Healthcare Holdings, EQT - TradingView
Weekly Earnings: Is ArriVent BioPharma Inc subject to activist investor interest2026 Price Swings & Fast Moving Market Watchlists - baoquankhu1.vn
Is ArriVent BioPharma (AVBP) Offering Value After Recent Share Price Pullback? - Sahm
Is ArriVent BioPharma, Inc. (AVBP) stock outpacing its medical peers this year? - MSN
ArriVent BioPharma Unveils Promising Preclinical Data on Firmonertinib and Dual-Target ADC ARR-002 at 2026 AACR Annual Meeting - Minichart
ArriVent BioPharma (AVBP) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Truist Securities Initiates Coverage of ArriVent BioPharma (AVBP) with Buy Recommendation - MSN
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting - The Manila Times
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026 - The National Law Review
ArriVent Highlights Next-Generation Oncology Data at AACR 2026 - TipRanks
ArriVent to present preclinical data on firmonertinib and dual-target ADC ARR-002 at AACR 2026 - TradingView
ArriVent BioPharma (AVBP) to showcase firmonertinib and ARR-002 preclinical data at AACR 2026 - Stock Titan
Lung and ovarian cancer drug data from ArriVent to debut at 2026 AACR - Stock Titan
Stock Report: What drives Assurant Incs stock price2026 Sentiment & Verified Entry Point Detection - baoquankhu1.vn
ArriVent BioPharma, Inc. $AVBP Shares Sold by Hidden Lake Asset Management LP - MarketBeat
Anson Funds Management LP Makes New Investment in ArriVent BioPharma, Inc. $AVBP - MarketBeat
ArriVent BioPharma (AVBP) Stock Analysis Report | Financials & Insights - Benzinga Japan
Suvretta Capital Management LLC Buys 290,664 Shares of ArriVent BioPharma, Inc. $AVBP - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Upgraded at BTIG Research - MarketBeat
Wall Street analysts see a 70.37% upside in ArriVent BioPharma, Inc. (AVBP): Can the stock really move this high? - MSN
Behavioral Patterns of AVBP and Institutional Flows - Stock Traders Daily
ArriVent BioPharma's (AVBP) Buy Rating Reaffirmed at BTIG Research - MarketBeat
ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target - TipRanks
BTIG initiates ArriVent stock coverage with buy rating on oncology pipeline - Investing.com Canada
ArriVent Reports 2025 Results, Plans Phase 3 Data for Firmonertinib - MyChesCo
ArriVent BioPharma (NASDAQ:AVBP) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Is ArriVent BioPharma, Inc. (AVBP) Shares Surpassing Other Medical Stocks in Performance This Year? - Bitget
Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High? - Yahoo Finance
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):